Literature DB >> 26351082

Determination of Voriconazole Concentrations in Serum by GC-MS.

Alisha Smith1, Van Leung-Pineda2.   

Abstract

BACKGROUND: Voriconazole is a broad spectrum triazole antifungal drug used to treat systemic fungal infections. Therapeutic drug monitoring of voriconazole is necessary for achieving maximal efficiency without inducing toxic side effects. Other publications have reported methods for measuring voriconazole in serum using high-performance liquid chromatography (HPLC) and liquid chromatography tandem mass spectrometry (LC-MS/MS). Here, we report for the first time a method for the measurement of voriconazole in serum samples using gas chromatography mass spectrometry (GC-MS).
METHODS: Protein precipitation with methanol was used to extract the antifungal that was derivatized with BSTFA (Sigma-Aldrich, St. Louis, MO) and analyzed by GC-MS. Linearity, sensitivity, precision, accuracy, and drug interferences were evaluated for this assay.
RESULTS: Our method was linear up to 10 μg/ml of voriconazole. The LOQ was determined to be 0.4 μg/ml. CV for between-day precision was <12%. Correlation with an established LC-MS/MS yielded a R2 of 0.96. Tested drugs did not result in >10% error in measurement.
CONCLUSION: To our knowledge, we report here the first GC-MS method for voriconazole measurement with acceptable performance. We hope that this method allows clinical laboratories without HPLC or LC-MS/MS instrumentation to measure voriconazole.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  antifungal; gas chromatography; mass spectrometry; therapeutic drug monitoring; triazole

Mesh:

Substances:

Year:  2015        PMID: 26351082      PMCID: PMC6807110          DOI: 10.1002/jcla.21871

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  14 in total

1.  Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors:  Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

2.  Fast and reliable determination of voriconazole in human plasma by LC-APCI-MS/MS.

Authors:  Xin Xiong; Jingli Duan; Suodi Zhai; Lijue Wang; Xi Lan
Journal:  Biosci Biotechnol Biochem       Date:  2010-10-07       Impact factor: 2.043

3.  In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.

Authors:  A Wildfeuer; H P Seidl; I Paule; A Haberreiter
Journal:  Mycoses       Date:  1998 Sep-Oct       Impact factor: 4.377

4.  Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.

Authors:  M Murphy; E M Bernard; T Ishimaru; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry.

Authors:  Fedja Farowski; Oliver A Cornely; Jörg J Vehreschild; Pia Hartmann; Tim Bauer; Angela Steinbach; Maria J G T Rüping; Carsten Müller
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

6.  Voriconazole: a new triazole antifungal.

Authors:  J A Sabo; S M Abdel-Rahman
Journal:  Ann Pharmacother       Date:  2000-09       Impact factor: 3.154

7.  Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.

Authors:  Andres Pascual; Valérie Nieth; Thierry Calandra; Jacques Bille; Saskia Bolay; Laurent A Decosterd; Thierry Buclin; Paul A Majcherczyk; Dominique Sanglard; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

8.  Measurement of voriconazole in serum and plasma.

Authors:  Loralie J Langman; Felix Boakye-Agyeman
Journal:  Clin Biochem       Date:  2007-08-16       Impact factor: 3.281

Review 9.  Voriconazole -- better chances for patients with invasive mycoses.

Authors:  Mahmoud A Ghannoum; D M Kuhn
Journal:  Eur J Med Res       Date:  2002-05-31       Impact factor: 2.175

10.  Recommendations for definition and determination of carry-over effects.

Authors:  R Haeckel
Journal:  J Automat Chem       Date:  1988
View more
  3 in total

1.  Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis.

Authors:  Sahar Yousefian; Farzaneh Dastan; Majid Marjani; Payam Tabarsi; Saghar Barati; Nahid Shahsavari; Farzad Kobarfard
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-04-12       Impact factor: 2.471

Review 2.  Assessment of greenness for the determination of voriconazole in reported analytical methods.

Authors:  Hemanth Kumar Chanduluru; Abimanyu Sugumaran
Journal:  RSC Adv       Date:  2022-02-28       Impact factor: 3.361

3.  Comparison of LC-MS3 and LC-MRM Method for Quantifying Voriconazole and Its Application in Therapeutic Drug Monitoring of Human Plasma.

Authors:  Wenbo Ren; Lei Yin; Gaixia Zhang; Taiyu Zhai; Jing Huang
Journal:  Molecules       Date:  2022-08-31       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.